tiprankstipranks
Advertisement
Advertisement

HK:2186 Stock Latest News

Luye Pharma Starts Phase II Trial in China for Next-Generation Schizophrenia Drug LY03020
Company AnnouncementsLuye Pharma Starts Phase II Trial in China for Next-Generation Schizophrenia Drug LY03020
5d ago
Luye Pharma Delivers Double-Digit Profit Growth in 2025 but Skips Dividend
PremiumCompany Announcements
Luye Pharma Delivers Double-Digit Profit Growth in 2025 but Skips Dividend
13d ago
Luye Pharma Sets March 2026 Board Meeting to Approve 2025 Results
PremiumCompany Announcements
Luye Pharma Sets March 2026 Board Meeting to Approve 2025 Results
27d ago
Luye Pharma Completes RMB1.09 Billion Transfer of 25% Stake in Nanjing Luye to NJ Xinshi
PremiumCompany Announcements
Luye Pharma Completes RMB1.09 Billion Transfer of 25% Stake in Nanjing Luye to NJ Xinshi
3M ago
Luye Pharma Injects RMB285 Million into Nanjing Unit via Structured Deal
PremiumCompany Announcements
Luye Pharma Injects RMB285 Million into Nanjing Unit via Structured Deal
3M ago
Luye Pharma’s Ruoxinlin NDA for Anxiety Disorder Accepted in China, Targeting Major CNS Market Gap
PremiumCompany AnnouncementsLuye Pharma’s Ruoxinlin NDA for Anxiety Disorder Accepted in China, Targeting Major CNS Market Gap
3M ago
Luye Pharma Adds Independent Director Xia Lian to Nomination Committee
Premium
Company Announcements
Luye Pharma Adds Independent Director Xia Lian to Nomination Committee
3M ago
Luye Pharma Outlines Board Line-Up and Committee Structure
Premium
Company Announcements
Luye Pharma Outlines Board Line-Up and Committee Structure
3M ago
Luye Pharma Tightens Governance With Updated Nomination Committee Mandate
PremiumCompany Announcements
Luye Pharma Tightens Governance With Updated Nomination Committee Mandate
3M ago
Luye Pharma Structures RMB1.09 Billion Nanjing Luye Stake Transfer With Options and Guarantees
PremiumCompany Announcements
Luye Pharma Structures RMB1.09 Billion Nanjing Luye Stake Transfer With Options and Guarantees
4M ago
Luye Pharma Grants Nhwa Exclusive China Rights for Three Long-Acting Schizophrenia Drugs
PremiumCompany Announcements
Luye Pharma Grants Nhwa Exclusive China Rights for Three Long-Acting Schizophrenia Drugs
4M ago
Luye Pharma Completes Strategic Issuance of Exchangeable Preference Shares
PremiumCompany Announcements
Luye Pharma Completes Strategic Issuance of Exchangeable Preference Shares
4M ago
Luye Pharma’s Five New Drugs Gain Inclusion in China’s 2025 Reimbursement Lists
PremiumCompany AnnouncementsLuye Pharma’s Five New Drugs Gain Inclusion in China’s 2025 Reimbursement Lists
4M ago
Luye Pharma Gains FDA Approval for New CNS Drug Trials
Premium
Company Announcements
Luye Pharma Gains FDA Approval for New CNS Drug Trials
5M ago
Luye Pharma Announces USD150 Million Exchangeable Shares Issuance
Premium
Company Announcements
Luye Pharma Announces USD150 Million Exchangeable Shares Issuance
5M ago
Luye Pharma Converts Convertible Bonds to Shares
PremiumCompany Announcements
Luye Pharma Converts Convertible Bonds to Shares
7M ago
Luye Pharma Converts $25 Million of Tranche A Bonds
PremiumCompany Announcements
Luye Pharma Converts $25 Million of Tranche A Bonds
7M ago
Luye Pharma Reports Revenue Growth Amid Profit Decline
PremiumCompany Announcements
Luye Pharma Reports Revenue Growth Amid Profit Decline
8M ago
Luye Pharma Reports Mixed Interim Financial Results for 2025
PremiumCompany Announcements
Luye Pharma Reports Mixed Interim Financial Results for 2025
8M ago
Luye Pharma Announces Partial Conversion of Convertible Bonds
PremiumCompany AnnouncementsLuye Pharma Announces Partial Conversion of Convertible Bonds
8M ago
Luye Pharma Group to Review Interim Results and Dividend
Premium
Company Announcements
Luye Pharma Group to Review Interim Results and Dividend
8M ago
Luye Pharma Completes Enrollment for Pioneering Anxiety Drug Trial
Premium
Company Announcements
Luye Pharma Completes Enrollment for Pioneering Anxiety Drug Trial
8M ago

Trending

Name
Price
Price Change
SPX
S&P 500
―
DJIA
Dow Jones
―
NDX
Nasdaq 100
―
More Trending Stocks >